浙江新光药业股份有限公司 《董事会提名委员会议事规则》 浙江新光药业股份有限公司 第五条 提名委员会委员必须符合下列条件： （一）不具有《公司法》或《公司章程》规定的不得担任公司董事、高级管 理人员的禁止性情形； （二）最近三年内不存在被证券交易所公开谴责或宣布为不适当人选的情形； （三）最近三年内不存在因重大违法违规行为被中国证监会予以行政处罚的 情形； 第二条 董事会提名委员会是董事会依据相应法律法规设立的专门工作机构， 对董事会负责并报告工作，主要负责对公司董事和高级管理人员的人选、选择标 准和程序进行选择并提出建议。 第二章 人员组成 第三条 提名委员会成员由三名董事组成，其中独立董事两名。 第四条 提名委员会委员由董事会选举产生。提名委员会设召集人一名，由 董事会选举一名独立董事委员担任，负责主持委员会工作。 董事会提名委员会议事规则 第一章 总则 第一条 为规范公司领导人员的产生，优化董事会组成，完善公司治理结构， 根据《中华人民共和国公司法》、《上市公司治理准则》、《公司章程》及其他有关 规定，公司特设立董事会提名委员会，并制订本议事规则。 （四）具备良好的道德品行，具有人力资源管理、企业管理、 ...

浙 江 新 光 药 业 股 份 有 限 公 司 《 董 事 和 高 级 管 理 人 员 薪 酬 管 理 制 度 》 浙江新光药业股份有限公司 董事和高级管理人员薪酬管理制度 第一章 总 则 第一条 为进一步完善浙江新光药业股份有限公司（以下简称"公司"）治理 结构，加强和规范公司董事和高级管理人员薪酬的管理，科学、客观、公正、规 范地评价公司董事、高级管理人员的经营业绩，建立和完善有效的激励与约束机 制，充分调动董事、高级管理人员的工作积极性和创造性，促进公司的持续健康 发展，根据《中华人民共和国公司法》（以下简称"《公司法》"）、《中华人民 共和国证券法》（以下简称"《证券法》"）等有关法律、法规、规章、规范性文 件及《浙江新光药业股份有限公司章程》（以下简称"《公司章程》"）的有关规 定，结合公司实际情况，制定《董事和高级管理人员薪酬管理制度》（以下简称 "本制度"）。 第二条 本制度所称董事、高级管理人员是指由股东会或董事会批准任命的 全体董事、总经理、副总经理、财务负责人、董事会秘书和公司章程规定的其他 高级管理人员。 第三条 公司董事、高级管理人员的薪酬以公司经营与综合管理情况为基础， 根据经营计划 ...

浙江新光药业股份有限公司 《董事离职管理制度》 浙江新光药业股份有限公司 董事离职管理制度 第一章 总则 第一条 为规范浙江新光药业股份有限公司（以下简称"公司"）董事和高 级管理人员离职管理，保障公司治理结构的稳定性和连续性，维护公司及股东 的合法权益，根据《中华人民共和国公司法》（以下简称"《公司法》"）《上 市公司章程指引》等法律法规及《浙江新光药业股份有限公司章程》（以下简称 "《公司章程》"）的有关规定，制定本制度。 第二条 本制度适用于公司全体董事（含独立董事）和高级管理人员的辞 任、任期届满、解任等离职情形。 第二章 离职情形与程序 第三条 公司董事、高级管理人员可以在任期届满以前提出辞职。 除法律法规、中国证监会和深圳证券交易所相关规则另有规定外，出现下 列规定情形的，在改选出的董事就任前，原董事仍应当依照法律、行政法规、 部门规章和《公司章程》规定，履行职务： （一）董事任期届满未及时改选，或者董事在任期内辞任导致董事会成员 低于法定最低人数； （二）审计委员会成员辞任导致审计委员会成员低于法定最低人数，或者 欠缺会计专业人士； （三）独立董事辞任导致公司董事会或者其专门委员会中独立董事所占 ...

浙江新光药业股份有限公司 《董事会薪酬与考核委员会议事规则》 浙江新光药业股份有限公司 董事会薪酬与考核委员会议事规则 第一章 总则 第一条 为进一步建立健全公司董事（非独立董事）及高级管理人员的考核 和薪酬管理制度，完善公司治理结构，根据《中华人民共和国公司法》、《上市公 司治理准则》、《公司章程》及其他有关规定，公司特设立董事会薪酬与考核委员 会，并制订本议事规则。 第二条 董事会薪酬与考核委员会是董事会依据相应法律法规设立的专门工 作机构，主要负责制定公司董事及高级管理人员的考核标准并进行考核；负责制 定、审查公司董事及高级管理人员的薪酬政策与方案，对董事会负责。 第三条 本规则所称董事是指在本公司支取薪酬的董事长、董事，高级管理 人员是指公司的总经理、副总经理、董事会秘书、财务负责人和公司章程规定的 其他人员。 第二章 人员组成 （二）最近三年内不存在被证券交易所公开谴责或宣布为不适当人选的情形； - 0 - 浙江新光药业股份有限公司 《董事会薪酬与考核委员会议事规则》 （三）最近三年不存在因重大违法违规行为被中国证监会予以行政处罚的情 形； （四）具备良好的道德品行，具有人力资源管理、企业管理、财务 ...

Group 1 - The company reported a revenue of 141 million yuan for the first half of the year, representing a year-on-year decrease of 3.60% [1] - The net profit attributable to shareholders was 31.91 million yuan, an increase of 25.09% compared to 25.51 million yuan in the same period last year [1] - The basic earnings per share were 0.2 yuan [1]

为全面贯彻落实最新法律法规要求，确保公司治理与监管规定保持同步，进 一步规范公司运作机制，提升公司治理水平，根据《公司法》、《证券法》、《上 市公司章程指引（2025 年 3 月修订）》、《深圳证券交易所创业板股票上市规 则》、《深圳证券交易所上市公司自律监管指引第 2 号——创业板上市公司规 范运作》等最新法律法规、规范性文件的要求，公司结合实际情况，对公司部分 治理制度进行修订和新增，具体情况如下： | 序号 | 制度名称 | 修订类型 | 是否提交股东会审议 | | --- | --- | --- | --- | | 1 | 《股东会议事规则》 | 修订 | 是 | | 2 | 《董事会议事规则》 | 修订 | 是 | | 3 | 《监事会议事规则》 | 废止 | 是 | | 4 | 《独立董事工作制度》 | 修订 | 是 | | 5 | 《募集资金管理制度》 | 修订 | 是 | | 6 | 《对外投资管理制度》 | 修订 | 是 | | 7 | 《对外担保决策制度》 | 修订 | 是 | | 8 | 《关联交易决策制度》 | 修订 | 是 | | 9 | 《公司董事会审计委员会议事规则》 | 修订 ...

经中国证券监督管理委员会证监许可〔2016〕1179 号文核准，本公司由主承销商太平 洋证券股份有限公司采用向社会公开发行方式，向社会公众公开发行人民币普通股（A 股） 股票 2,000 万股，发行价为每股人民币 12.20 元，共计募集资金 24,400.00 万元，扣除发行 费用 3,233.00 万元后，公司本次实际募集资金净额为 21,167.00 万元。上述募集资金到位情 况业经天健会计师事务所（特殊普通合伙）验证，并由其出具《验资报告》（天健验〔2016〕 203 号）。 (二) 募集资金使用和结余情况 浙江新光药业股份有限公司 关于 2025 年半年度募集资金存放与使用情况的专项报告 根据中国证券监督管理委员会《上市公司监管指引第 2 号——上市公司募集资金管理和 使用的监管要求（2022 年修订）》（证监会公告〔2022〕15 号）和深圳证券交易所印发的 深圳证券交易所上市公司自律监管指引第 2 号——创业板上市公司规范运作》（深证上〔2022〕 14 号）的规定，将本公司募集资金 2025 年上半年存放与使用情况专项说明如下。 一、募集资金基本情况 (一)实际募集资金金额和资金到账时间 截至 ...

证券代码：300519 证券简称：新光药业 公告编号：2025-023 浙江新光药业股份有限公司 关于修订《公司章程》的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 浙江新光药业股份有限公司（以下简称"公司"）于 2025 年 8 月 23 日召 开第五届董事会第五次会议和第五届监事会第五次会议，审议通过了《关于修订 <公司章程>及办理工商登记的议案》，现将有关情况公告如下： 根据《公司法》、《证券法》、《深圳证券交易所创业板股票上市规则》、 《深圳证券交易所上市公司自律监管指引第 2 号——创业板上市公司规范运 作》、中国证券监督管理委员会发布的《关于新<公司法>配套制度规则实施相关 过渡期安排》《上市公司章程指引（2025 年 3 月修订）》等相关法律法规的规 定，结合公司实际情况，公司将不再设置监事会和监事，监事会的职权由董事会 审计委员会行使，公司监事会相关制度相应废止。同时公司董事会拟对公司章程 的相关条款进行修订更新。修订后的《公司章程》将提交公司 2025 年第一次临 时股东大会审议，并提请股东大会授权董事会办理《公司章程》变更及相关工商 ...

法定代表人： 主管会计工作的负责人： 会计机构负责人： | 非经营性资金占用 | 资金占用方名 称 | 占用方与上市公 司的关联关系 | 上市公司核算 | 2025 年期初 | 2025 年 1-6 月占 用累计发生金额 | 2025 年 1-6 月占 用资金的利息 | 2025 年 1-6 月 偿还累计发生 | 2025 年 6 月末 | 占用形成 | 占用性质 | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | | | | 的会计科目 | 占用资金余额 | （不含利息） | （如有） | 金额 | 占用资金余额 | 原因 | | | 控股股东、实际控制 | | | | | | | | | | | | 人及其附属企业 | | | | | | | | | | | | 小 计 | | | | | | | | | | | | 前控股股东、实际控 | | | | | | | | | | | | 制人及其附属企业 | | | | | | | | | | | | 小 计 | | | | | | | | | | | | 其他关联方 ...

[Important Notices, Contents and Definitions](index=2&type=section&id=Section%201%20Important%20Notices%2C%20Contents%20and%20Definitions) [Important Notices](index=2&type=section&id=1.1%20Important%20Notices) The company's management guarantees the truthfulness and accuracy of the semi-annual report and plans no profit distribution - The Board of Directors, Supervisory Committee, and senior management guarantee the truthfulness, accuracy, and completeness of the semi-annual report, and bear individual and joint legal responsibility[4](index=4&type=chunk) - The company's legal representative, chief financial officer, and head of the accounting department declare that the financial report is true, accurate, and complete[4](index=4&type=chunk) - The company **does not plan to distribute cash dividends**, issue bonus shares, or convert capital reserves into share capital[5](index=5&type=chunk) [Contents](index=3&type=section&id=1.2%20Contents) This section lists the overall structure of the report, providing a quick navigation guide for investors - The table of contents clearly lists eight main sections, covering important notices, company profile, management discussion, corporate governance, significant matters, share changes, bonds, and financial reports[7](index=7&type=chunk) [Definitions](index=5&type=section&id=1.3%20Definitions) This section provides definitions for common terms used in the report to ensure consistent understanding - "Xinguang Pharmaceutical," "the Company," and "our Company" all refer to Zhejiang Xinguang Pharmaceutical Co, Ltd[10](index=10&type=chunk) - "Reporting Period" and "this Reporting Period" refer to the period from January 1, 2025, to June 30, 2025[10](index=10&type=chunk) - "NMPA" refers to the National Medical Products Administration, and "GMP" refers to the Good Manufacturing Practice for Pharmaceutical Products[10](index=10&type=chunk) [Company Profile and Key Financial Indicators](index=6&type=section&id=Section%202%20Company%20Profile%20and%20Key%20Financial%20Indicators) [Company Profile](index=6&type=section&id=2.1%20Company%20Profile) Zhejiang Xinguang Pharmaceutical Co, Ltd is listed on the Shenzhen Stock Exchange with stock code 300519 Company Basic Information | Indicator | Content | | :--- | :--- | | Stock Abbreviation | Xinguang Pharmaceutical | | Stock Code | 300519 | | Listing Exchange | Shenzhen Stock Exchange | | Chinese Name | 浙江新光药业股份有限公司 | | Legal Representative | Wang Yuejun | - The company's contact information, including registered address, office address, website, and email, remained unchanged during the reporting period[14](index=14&type=chunk) [Key Accounting Data and Financial Indicators](index=7&type=section&id=2.2%20Key%20Accounting%20Data%20and%20Financial%20Indicators) In H1 2025, revenue decreased while net profit attributable to shareholders grew significantly by 25.09% Key Accounting Data and Financial Indicators for H1 2025 | Indicator | Current Period (CNY) | Prior Year Period (CNY) | Y-o-Y Change | | :--- | :--- | :--- | :--- | | Operating Revenue | 140,942,929.20 | 146,210,038.02 | -3.60% | | Net Profit Attributable to Shareholders | 31,907,696.41 | 25,507,669.29 | 25.09% | | Net Profit Attributable to Shareholders (Excluding Non-recurring Items) | 29,439,271.34 | 22,574,542.06 | 30.41% | | Net Cash Flow from Operating Activities | 36,827,143.99 | 27,126,609.63 | 35.76% | | Basic Earnings Per Share (CNY/Share) | 0.20 | 0.16 | 25.00% | | Weighted Average Return on Equity | 3.80% | 3.01% | 0.79% | | Indicator | End of Current Period (CNY) | End of Prior Year (CNY) | Change from Prior Year-End | | :--- | :--- | :--- | :--- | | Total Assets | 879,939,726.63 | 909,781,335.37 | -3.28% | | Net Assets Attributable to Shareholders | 814,658,032.16 | 830,531,829.60 | -1.91% | - There are no discrepancies in net profit or net assets between financial reports prepared under IFRS and Chinese Accounting Standards[18](index=18&type=chunk) [Non-recurring Profit and Loss Items and Amounts](index=7&type=section&id=2.3%20Non-recurring%20Profit%20and%20Loss%20Items%20and%20Amounts) Non-recurring profit and loss totaled CNY 2.47 million, mainly from government subsidies and fair value changes Non-recurring Profit and Loss Items and Amounts for H1 2025 | Item | Amount (CNY) | Notes | | :--- | :--- | :--- | | Gains/Losses on Disposal of Non-current Assets | -20,128.57 | | | Government Subsidies Included in Current Profit/Loss | 885,843.80 | Government subsidies received this period | | Fair Value Gains/Losses on Financial Assets and Liabilities | 1,799,444.32 | | | Other Non-operating Income and Expenses | 229,899.70 | | | Less: Income Tax Impact | 426,634.18 | | | Total | 2,468,425.07 | | - The company has no other items that meet the definition of non-recurring profit and loss, nor has it reclassified any non-recurring items as recurring[22](index=22&type=chunk) [Management Discussion and Analysis](index=9&type=section&id=Section%203%20Management%20Discussion%20and%20Analysis) [Principal Business Activities during the Reporting Period](index=9&type=section&id=3.1%20Principal%20Business%20Activities%20during%20the%20Reporting%20Period) The company engages in the R&D, production, and sale of traditional Chinese medicines, chemical drugs, and health foods - The company operates in the pharmaceutical manufacturing industry, benefiting from national support for traditional Chinese medicine and an aging population[24](index=24&type=chunk) - In H1 2025, intensive medical policy rollouts, including medical insurance catalog expansion and the promotion of traditional Chinese medicine, reshaped the industry[25](index=25&type=chunk) - The company is primarily engaged in the R&D, production, and sale of traditional Chinese medicines, chemical drugs, and health foods, holding 49 drug production licenses and 2 health food licenses[26](index=26&type=chunk)[27](index=27&type=chunk) [Industry Overview](index=9&type=section&id=3.1.1%20Industry%20Overview) The pharmaceutical manufacturing industry is a vital part of the national economy, with strong policy support for traditional Chinese medicine - The pharmaceutical industry is a key component of the national economy, with traditional Chinese medicine development receiving significant policy support, such as the "Three-Year Action Plan for the Revitalization and Development of Traditional Chinese Medicine (2025-2027)"[24](index=24&type=chunk)[25](index=25&type=chunk) - As of December 2024, China's elderly population (60 and above) reached **310 million**, accounting for **22% of the total population**, a demographic trend that will continue to drive pharmaceutical industry growth[24](index=24&type=chunk) [Main Business](index=9&type=section&id=3.1.2%20Main%20Business) The company's main business remains unchanged, focusing on pharmaceuticals and health foods across various therapeutic areas - The company's primary business involves the R&D, production, and sale of traditional Chinese medicines, chemical drugs, and health foods, covering a wide range of therapeutic areas[26](index=26&type=chunk) - The company can produce 6 dosage forms and holds **49 drug production licenses** and **2 health food licenses**[27](index=27&type=chunk) [Main Products](index=9&type=section&id=3.1.3%20Main%20Products) Key products include Huangqi Shengmai Yin, Shenjin Dan Capsules, and American Ginseng Oral Liquid Company's Main Product Indications | Category | Product Name | Indications | Remarks | | :--- | :--- | :--- | :--- | | Traditional Chinese Medicine | Huangqi Shengmai Yin | To replenish qi and nourish yin, nourish the heart and lungs, for coronary heart disease patients with qi and yin deficiency, palpitations, and shortness of breath | First-to-market product | | Traditional Chinese Medicine | Shenjin Dan Capsules | To relax muscles and activate collaterals, promote blood circulation and remove blood stasis, reduce swelling and relieve pain, for sequelae of fractures, cervical spondylosis, etc | | | Health Food | American Ginseng Oral Liquid | A health food made mainly from American ginseng, with anti-fatigue health benefits | | | Traditional Chinese Medicine | Huangqi Shengmai Granules | To replenish qi and nourish yin, nourish the heart and promote circulation, for chest pain and tightness caused by qi and yin deficiency and blood stasis | Exclusive product | [Operating Model](index=9&type=section&id=3.1.4%20Operating%20Model) The company employs a "procure-by-production" and "produce-by-sales" model, distributing products through dealers - Procurement Model: "Procure-by-production" based on production plans, inventory, and market conditions, with strict management of Chinese herbal medicine procurement[27](index=27&type=chunk) - Production Model: "Produce-by-sales" based on annual sales plans, with production organized in strict accordance with national GMP regulations and comprehensive quality management[28](index=28&type=chunk) - Sales Model: Primarily through distributors, who then supply products to retail terminals such as hospitals, pharmacies, and clinics[28](index=28&type=chunk) [Main Performance Drivers during the Reporting Period](index=10&type=section&id=3.1.5%20Main%20Performance%20Drivers%20during%20the%20Reporting%20Period) Performance is driven by rising incomes, expanded medical insurance, an aging population, and healthcare system reforms - Rising resident income and consumption levels, along with increased coverage and payment rates for urban and rural medical insurance, are key performance drivers[29](index=29&type=chunk) - Population aging, the multi-child policy, and deepening healthcare system reforms are among the various factors driving sustained growth in the pharmaceutical industry[29](index=29&type=chunk) [Core Competitiveness Analysis](index=11&type=section&id=3.2%20Core%20Competitiveness%20Analysis) The company's core competitiveness remains stable, centered on product advantages, quality control, brand image, and R&D innovation - The company's core competitiveness has not changed significantly, with strong advantages in leading products, product quality, corporate brand, R&D, and process technology[30](index=30&type=chunk) - Leading products **Huangqi Shengmai Yin** and **Shenjin Dan Capsules** have broad market prospects, with a sugar-free version and an exclusive granule form of Huangqi Shengmai developed to meet market demand[30](index=30&type=chunk)[31](index=31&type=chunk) - The company operates a provincial-level high-tech R&D center, collaborates with multiple research institutions, and holds **11 core proprietary intellectual property rights**[31](index=31&type=chunk) - The company utilizes advanced production technologies and has introduced a fully automated digital traditional Chinese medicine extraction production line[32](index=32&type=chunk)[33](index=33&type=chunk) [Main Business Analysis](index=12&type=section&id=3.3%20Main%20Business%20Analysis) Revenue declined slightly, but lower costs and higher financial income boosted net profit by 25.09% Year-on-Year Changes in Key Financial Data | Indicator | Current Period (CNY) | Prior Year Period (CNY) | Y-o-Y Change | Reason for Change | | :--- | :--- | :--- | :--- | :--- | | Operating Revenue | 140,942,929.20 | 146,210,038.02 | -3.60% | | | Operating Costs | 89,363,811.65 | 96,499,935.86 | -7.39% | Primarily due to lower raw material prices compared to the same period last year | | Financial Expenses | -10,658,993.74 | -3,855,390.27 | -176.47% | Primarily due to an increase in bank deposit interest income compared to the same period last year | | Operating Profit | 36,071,990.19 | 28,382,629.30 | 27.09% | Primarily due to decreased operating costs and increased interest income | | Net Profit | 31,907,696.41 | 25,507,669.29 | 25.09% | Primarily due to decreased operating costs and increased interest income | Products or Services Accounting for Over 10% of Revenue | Product Name | Operating Revenue (CNY) | Operating Costs (CNY) | Gross Margin | Revenue Y-o-Y Change | Cost Y-o-Y Change | Gross Margin Y-o-Y Change | | :--- | :--- | :--- | :--- | :--- | :--- | :--- | | Huangqi Shengmai Yin | 98,439,572.93 | 62,190,606.85 | 36.82% | -6.41% | -10.43% | 2.83% | | Shenjin Dan Capsules | 11,804,196.55 | 6,838,752.05 | 42.07% | -3.06% | -12.61% | 6.33% | | American Ginseng Oral Liquid | 28,134,440.52 | 17,312,671.75 | 38.46% | 11.56% | 10.71% | 0.47% | - There were no significant changes in the company's profit composition or sources of profit during the reporting period[36](index=36&type=chunk) [Non-Main Business Analysis](index=13&type=section&id=3.4%20Non-Main%20Business%20Analysis) Non-main business income primarily consists of investment income and government subsidies, contributing 6.02% to total profit Composition of Non-Main Business Income | Item | Amount (CNY) | % of Total Profit | Reason | Sustainability | | :--- | :--- | :--- | :--- | :--- | | Investment Income | 2,185,287.20 | 6.02% | 1. Wealth management product income CNY 1,799,444.32; 2. Other equity instrument investment income CNY 240,000.00; 3. Stock investment income CNY 145,842.88 | No | | Asset Impairment | -177,676.58 | -0.49% | Provision for inventory write-down (loss shown with "-") | Impairment provision is made at each year-end according to accounting standards | | Other Income | 1,305,497.17 | 3.60% | 1. Amortization of asset-related government grants CNY 692,974.80; 2. Income-related government grants CNY 576,535.08; 3. Individual income tax withholding fee refund CNY 35,987.29 | No | [Analysis of Assets and Liabilities](index=14&type=section&id=3.5%20Analysis%20of%20Assets%20and%20Liabilities) Total assets decreased by 3.28%, with cash decreasing due to increased investment in wealth management products Significant Changes in Asset Composition | Item | Current Period-End Amount (CNY) | % of Total Assets | Prior Year-End Amount (CNY) | % of Total Assets | Change in Proportion | Reason for Significant Change | | :--- | :--- | :--- | :--- | :--- | :--- | :--- | | Cash and Cash Equivalents | 306,321,596.05 | 34.81% | 503,416,125.46 | 55.33% | -20.52% | Increase in purchases of wealth management products | | Trading Financial Assets | 370,000,000.00 | 42.05% | 185,000,000.00 | 20.33% | 21.72% | | | Total Assets | 879,939,726.63 | 100.00% | 909,781,335.37 | 100.00% | -3.28% | | | Total Liabilities | 65,281,694.47 | 7.42% | 79,249,505.77 | 8.71% | -17.62% | | | Net Assets Attributable to Shareholders | 814,658,032.16 | 92.58% | 830,531,829.60 | 91.29% | -1.91% | | Assets and Liabilities Measured at Fair Value | Item | Opening Balance (CNY) | Current Period Fair Value Change (CNY) | Current Period Purchases (CNY) | Current Period Sales (CNY) | Closing Balance (CNY) | | :--- | :--- | :--- | :--- | :--- | :--- | | Trading Financial Assets | 185,000,000.00 | 1,799,444.32 | 420,000,000.00 | 236,799,444.32 | 370,000,000.00 | | Other Equity Instrument Investments | 21,420,408.13 | 257,066.07 | 0.00 | 0.00 | 21,677,474.20 | | Total | 206,420,408.13 | 2,056,510.39 | 420,000,000.00 | 236,799,444.32 | 391,677,474.20 | - At the end of the reporting period, notes receivable decreased by CNY 502,745.60[45](index=45&type=chunk) [Investment Analysis](index=15&type=section&id=3.6%20Investment%20Analysis) The company had no major equity investments, utilized 74.20% of raised funds, and continued cash management with idle funds Financial Assets Measured at Fair Value | Asset Class | Initial Investment Cost (CNY) | Current Period Fair Value Change (CNY) | Period-End Amount (CNY) | Funding Source | | :--- | :--- | :--- | :--- | :--- | | Stocks | 510,890.50 | 115,017.87 | 2,823,165.90 | Own funds | | Stocks | 120,000.00 | 142,048.20 | 1,954,308.30 | Own funds | | Total | 630,890.50 | 257,066.07 | 4,777,474.20 | -- | - As of June 30, 2025, the total amount of raised funds was **CNY 211.67 million**, with a cumulative usage of **CNY 157.06 million**, resulting in an overall utilization rate of **74.20%**[48](index=48&type=chunk) - The "Modern Traditional Chinese Medicine R&D Center Construction Project" has been completed, and the surplus funds of **CNY 17,329,671.05** have been permanently used to supplement working capital[51](index=51&type=chunk)[97](index=97&type=chunk) - The company continues to use up to **CNY 400 million** of idle proprietary funds and up to **CNY 15 million** of temporarily idle raised funds for cash management by purchasing low-risk, high-liquidity bank wealth management products[59](index=59&type=chunk) [Sale of Major Assets and Equity](index=22&type=section&id=3.7%20Sale%20of%20Major%20Assets%20and%20Equity) No major asset or equity sales occurred during the reporting period - The company did not sell any major assets during the reporting period[62](index=62&type=chunk) - The company did not sell any major equity during the reporting period[63](index=63&type=chunk) [Analysis of Major Subsidiaries and Investees](index=22&type=section&id=3.8%20Analysis%20of%20Major%20Subsidiaries%20and%20Investees) The main subsidiary, Zhejiang Xinguang Pharmaceutical Technology, reported a net profit of CNY 0.74 million Financial Information of Main Subsidiary | Company Name | Company Type | Main Business | Registered Capital (CNY) | Total Assets (CNY) | Net Assets (CNY) | Operating Revenue (CNY) | Operating Profit (CNY) | Net Profit (CNY) | | :--- | :--- | :--- | :--- | :--- | :--- | :--- | :--- | :--- | | Zhejiang Xinguang Pharmaceutical Technology Co, Ltd | Subsidiary | R&D and sales of traditional Chinese medicines, health foods, pharmaceuticals, food, medical devices, etc | 35,000,000.00 | 41,571,756.69 | 38,834,071.51 | 7,831,504.42 | 783,340.64 | 744,173.61 | - Zhejiang Xinguang Pharmaceutical Technology Co, Ltd is a wholly-owned subsidiary of the company, with a 100% equity stake[65](index=65&type=chunk) [Risks and Countermeasures](index=23&type=section&id=3.9%20Risks%20and%20Countermeasures) The company faces risks from policy changes, product concentration, market expansion, and raw material price volatility - **Policy Change Risk**: Stricter national regulations on drug production and sales, such as the "two-invoice system" and "volume-based procurement," may impact the company's operations[66](index=66&type=chunk) - **Product Concentration Risk**: The company's revenue and profitability are heavily dependent on three main products, creating a risk of product structure concentration[67](index=67&type=chunk) - **Market Expansion Risk**: Over **70% of sales revenue** comes from Zhejiang Province, posing a risk of adverse performance impact from changes in the regional market environment[67](index=67&type=chunk) - **Raw Material Price Fluctuation Risk**: Significant increases in the prices of major Chinese herbal medicines, influenced by various factors, could adversely affect the company's profitability[68](index=68&type=chunk) [Corporate Governance, Environment and Society](index=24&type=section&id=Section%204%20Corporate%20Governance%2C%20Environment%20and%20Society) [Changes in Directors, Supervisors, and Senior Management](index=24&type=section&id=4.1%20Changes%20in%20Directors%2C%20Supervisors%2C%20and%20Senior%20Management) No changes occurred in the composition of the company's directors, supervisors, or senior management during the period - There were no changes in the company's directors, supervisors, and senior management during the reporting period[71](index=71&type=chunk) [Profit Distribution and Capitalization of Capital Reserve for the Reporting Period](index=24&type=section&id=4.2%20Profit%20Distribution%20and%20Capitalization%20of%20Capital%20Reserve%20for%20the%20Reporting%20Period) The company does not plan to distribute profits or capitalize capital reserves for the semi-annual period - The company plans **not to distribute cash dividends**, issue bonus shares, or convert capital reserves into share capital for the semi-annual period[72](index=72&type=chunk) [Implementation of Equity Incentive Plans, Employee Stock Ownership Plans, or Other Employee Incentive Measures](index=25&type=section&id=4.3%20Implementation%20of%20Equity%20Incentive%20Plans%2C%20Employee%20Stock%20Ownership%20Plans%2C%20or%20Other%20Employee%20Incentive%20Measures) No equity incentive plans or other employee incentive measures were implemented during the reporting period - The company had no equity incentive plans, employee stock ownership plans, or other employee incentive measures and their implementation during the reporting period[73](index=73&type=chunk) [Environmental Information Disclosure](index=26&type=section&id=4.4%20Environmental%20Information%20Disclosure) The company and its main subsidiaries are not listed as enterprises required to disclose environmental information - The listed company and its main subsidiaries are not included in the list of enterprises required to disclose environmental information by law[74](index=74&type=chunk) [Social Responsibility](index=26&type=section&id=4.5%20Social%20Responsibility) The company is committed to its corporate mission and values, focusing on operational excellence and social responsibility - The company's core values are "Pragmatism, Integrity, Responsibility," and its corporate mission is "To improve the quality of human life and share a new era of health"[74](index=74&type=chunk) - During the reporting period, the company actively adapted to policy changes, enhanced management, strengthened its marketing network, and fulfilled its social responsibilities[74](index=74&type=chunk) - The company has not yet carried out work to consolidate and expand poverty alleviation achievements or rural revitalization during the reporting period[74](index=74&type=chunk) [Significant Matters](index=27&type=section&id=Section%205%20Significant%20Matters) [Fulfillment of Commitments](index=27&type=section&id=5.1%20Fulfillment%20of%20Commitments) There were no fulfilled or overdue commitments from related parties during the reporting period - During the reporting period, there were no commitments fulfilled or overdue by the company's actual controllers, shareholders, related parties, acquirers, or the company itself[76](index=76&type=chunk) [Non-operating Fund Occupation by Controlling Shareholders and Other Related Parties](index=27&type=section&id=5.2%20Non-operating%20Fund%20Occupation%20by%20Controlling%20Shareholders%20and%20Other%20Related%20Parties) No non-operating fund occupation by controlling shareholders or other related parties occurred during the period - The company did not experience any non-operating fund occupation by its controlling shareholder or other related parties during the reporting period[77](index=77&type=chunk) [Irregular External Guarantees](index=27&type=section&id=5.3%20Irregular%20External%20Guarantees) The company had no irregular external guarantees during the reporting period - The company had no irregular external guarantees during the reporting period[78](index=78&type=chunk) [Appointment and Dismissal of Accounting Firm](index=27&type=section&id=5.4%20Appointment%20and%20Dismissal%20of%20Accounting%20Firm) The company's semi-annual financial report has not been audited - The company's semi-annual report has not been audited[79](index=79&type=chunk) [Litigation Matters](index=27&type=section&id=5.5%20Litigation%20Matters) No major litigation or arbitration matters occurred during the reporting period - The company had no major litigation or arbitration matters during this reporting period[81](index=81&type=chunk) [Penalties and Rectifications](index=28&type=section&id=5.6%20Penalties%20and%20Rectifications) The company was not subject to any penalties or rectifications during the reporting period - The company was not subject to any penalties or rectifications during the reporting period[82](index=82&type=chunk) [Major Related-Party Transactions](index=28&type=section&id=5.7%20Major%20Related-Party%20Transactions) No major related-party transactions occurred during the reporting period - The company had no related-party transactions associated with daily operations during the reporting period[83](index=83&type=chunk) - There were no related-party credit or debt transactions during the reporting period[86](index=86&type=chunk) - The company had no other major related-party transactions during the reporting period[89](index=89&type=chunk) [Major Contracts and Their Performance](index=29&type=section&id=5.8%20Major%20Contracts%20and%20Their%20Performance) The company has no major contracts for custody or contracting but has one leasing agreement as a lessor - The company had no custody arrangements during the reporting period[90](index=90&type=chunk) - The company leased four storefronts at 699 Jiangbin West Road to Zhejiang Zhenyuan Pharmaceutical Chain Co, Ltd, with the contract renewed until December 31, 2025, for an annual rent of **CNY 73,728.00** (including tax)[92](index=92&type=chunk) - The company had no major guarantees during the reporting period[93](index=93&type=chunk) [Explanation of Other Significant Matters](index=29&type=section&id=5.9%20Explanation%20of%20Other%20Significant%20Matters) The "Modern Traditional Chinese Medicine R&D Center" project was completed, and surplus funds were used for working capital - The "Modern Traditional Chinese Medicine R&D Center Construction Project" built by the company's wholly-owned subsidiary, Zhejiang Xinguang Pharmaceutical Technology Co, Ltd, has been completed[97](index=97&type=chunk) - As of May 30, 2025, the surplus raised funds of **CNY 17,329,671.05** (including interest and wealth management income) have been transferred to the subsidiary's basic account to permanently supplement working capital[97](index=97&type=chunk) - The aforementioned special account for raised funds has been closed, and the tripartite supervision agreement signed by the company, the bank, and the sponsor has been terminated accordingly[97](index=97&type=chunk) [Changes in Share Capital and Shareholders](index=31&type=section&id=Section%206%20Changes%20in%20Share%20Capital%20and%20Shareholders) [Changes in Share Capital](index=31&type=section&id=6.1%20Changes%20in%20Share%20Capital) The company's total share capital remained unchanged at 160 million shares during the reporting period Changes in Share Capital | Share Type | Pre-Change Quantity (Shares) | Pre-Change Proportion | Change (+/- Shares) | Post-Change Quantity (Shares) | Post-Change Proportion | | :--- | :--- | :--- | :--- | :--- | :--- | | I. Shares with Selling Restrictions | 45,900,000 | 28.69% | 0 | 45,900,000 | 28.69% | | Of which: Domestic Natural Person Shares | 45,900,000 | 28.69% | 0 | 45,900,000 | 28.69% | | II. Shares without Selling Restrictions | 114,100,000 | 71.31% | 0 | 114,100,000 | 71.31% | | Of which: RMB Ordinary Shares | 114,100,000 | 71.31% | 0 | 114,100,000 | 71.31% | | III. Total Shares | 160,000,000 | 100.00% | 0 | 160,000,000 | 100.00% | - There were no changes in the reasons for share capital changes, approvals, transfers, or share repurchase implementation during the reporting period[102](index=102&type=chunk) [Securities Issuance and Listing](index=32&type=section&id=6.2%20Securities%20Issuance%20and%20Listing) No securities were issued or listed during the reporting period - The company had no securities issuance or listing activities during the reporting period[102](index=102&type=chunk) [Number of Shareholders and Shareholding Status](index=32&type=section&id=6.3%20Number%20of%20Shareholders%20and%20Shareholding%20Status) As of the period-end, the company had 14,146 shareholders, with Wang Yuejun being the largest shareholder at 38.25% - The total number of ordinary shareholders at the end of the reporting period was **14,146**[103](index=103&type=chunk) Top 10 Shareholders | Shareholder Name | Shareholder Type | Shareholding Ratio | Shares Held at Period-End | Restricted Shares Held | Unrestricted Shares Held | Share Status | | :--- | :--- | :--- | :--- | :--- | :--- | :--- | | Wang Yuejun | Domestic Natural Person | 38.25% | 61,200,000.00 | 45,900,000.00 | 15,300,000.00 | N/A | | Shengzhou Hefeng Investment Co, Ltd | Domestic Non-State-Owned Legal Entity | 16.74% | 26,780,900.00 | 0 | 26,780,900.00 | N/A | | Mo Changchun | Domestic Natural Person | 1.18% | 1,894,800.00 | 0 | 1,894,800.00 | N/A | | Qian Haixiao | Domestic Natural Person | 0.95% | 1,520,000.00 | 0 | 1,520,000.00 | N/A | | China Minsheng Bank - Golden Yuan Sunan Yuanqi Flexible Allocation Mixed Fund | Other | 0.54% | 867,600.00 | 0 | 867,600.00 | N/A | | BARCLAYS BANK PLC | Foreign Legal Entity | 0.49% | 778,500.00 | 0 | 778,500.00 | N/A | | China Construction Bank - Lion Multi-Strategy Equity Fund | Other | 0.43% | 692,344.00 | 0 | 692,344.00 | N/A | | Zhou Huichu | Domestic Natural Person | 0.43% | 690,000.00 | 0 | 690,000.00 | N/A | | Tan Yonghua | Domestic Natural Person | 0.35% | 557,500.00 | 0 | 557,500.00 | N/A | | Mo Junlong | Domestic Natural Person | 0.30% | 486,300.00 | 0 | 486,300.00 | N/A | - There is no affiliation or concerted action relationship between shareholder Wang Yuejun and Shengzhou Hefeng Investment Co, Ltd[104](index=104&type=chunk) [Changes in Shareholdings of Directors, Supervisors, and Senior Management](index=34&type=section&id=6.4%20Changes%20in%20Shareholdings%20of%20Directors%2C%20Supervisors%2C%20and%20Senior%20Management) The shareholdings of directors, supervisors, and senior management remained unchanged during the reporting period - The shareholdings of the company's directors, supervisors, and senior management did not change during the reporting period[106](index=106&type=chunk) [Changes in Controlling Shareholder or Actual Controller](index=34&type=section&id=6.5%20Changes%20in%20Controlling%20Shareholder%20or%20Actual%20Controller) No changes occurred in the company's controlling shareholder or actual controller during the period - The company's controlling shareholder did not change during the reporting period[107](index=107&type=chunk) - The company's actual controller did not change during the reporting period[107](index=107&type=chunk) [Bond-related Matters](index=36&type=section&id=Section%207%20Bond-related%20Matters) [Bond-related Matters](index=36&type=section&id=7.1%20Bond-related%20Matters) The company has no bond-related matters to report for this period - The company has no bond-related matters to report for this period[110](index=110&type=chunk) [Financial Report](index=37&type=section&id=Section%208%20Financial%20Report) [Audit Report](index=37&type=section&id=8.1%20Audit%20Report) The semi-annual financial report has not been audited - The company's semi-annual financial report has not been audited[112](index=112&type=chunk) [Financial Statements](index=37&type=section&id=8.2%20Financial%20Statements) This section presents the company's financial statements for H1 2025, showing total assets of CNY 880 million Key Data from Consolidated Balance Sheet (Period-End) | Item | Closing Balance (CNY) | | :--- | :--- | | Total Assets | 879,939,726.63 | | Total Liabilities | 65,281,694.47 | | Total Equity | 814,658,032.16 | | Cash and Cash Equivalents | 306,321,596.05 | | Trading Financial Assets | 370,000,000.00 | | Inventories | 61,596,098.12 | Key Data from Consolidated Income Statement (Current Period) | Item | H1 2025 (CNY) | | :--- | :--- | | Total Operating Revenue | 140,942,929.20 | | Operating Profit | 36,071,990.19 | | Total Profit | 36,285,483.59 | | Net Profit | 31,907,696.41 | | Net Profit Attributable to Parent Company Owners | 31,907,696.41 | | Basic Earnings Per Share | 0.20 | Key Data from Consolidated Cash Flow Statement (Current Period) | Item | H1 2025 (CNY) | | :--- | :--- | | Net Cash Flow from Operating Activities | 36,827,143.99 | | Net Cash Flow from Investing Activities | -185,921,673.40 | | Net Cash Flow from Financing Activities | -48,000,000.00 | | Net Increase in Cash and Cash Equivalents | -197,094,529.41 | | Closing Balance of Cash and Cash Equivalents | 306,321,596.05 | [Company's Basic Information](index=55&type=section&id=8.3%20Company's%20Basic%20Information) Zhejiang Xinguang Pharmaceutical Co, Ltd, established in 1998, is a listed company engaged in pharmaceutical manufacturing - The company was established on November 18, 1998, with a registered capital of **CNY 160 million** and a total of **160 million shares**, and was listed on the Shenzhen Stock Exchange on June 24, 2016[144](index=144&type=chunk) - The company belongs to the pharmaceutical manufacturing industry, with a business scope covering the production and sale of various dosage forms and health foods[144](index=144&type=chunk) - The subsidiary, Zhejiang Xinguang Pharmaceutical Technology Co, Ltd, is included in the scope of the consolidated financial statements for this period[145](index=145&type=chunk) [Basis of Preparation of Financial Statements](index=55&type=section&id=8.4%20Basis%20of%20Preparation%20of%20Financial%20Statements) The financial statements are prepared on a going concern basis, with no significant doubts about this ability - The company's financial statements are prepared on a going concern basis[146](index=146&type=chunk) - The company has no events or conditions that cast significant doubt on its ability to continue as a going concern for the next 12 months from the end of the reporting period[147](index=147&type=chunk) [Significant Accounting Policies and Estimates](index=55&type=section&id=8.5%20Significant%20Accounting%20Policies%20and%20Estimates) This section details the key accounting policies and estimates used in preparing the financial statements - The financial statements prepared by the company comply with the requirements of the "Enterprise Accounting Standards" and provide a true and complete view of the company's financial position, operating results, and cash flows[149](index=149&type=chunk) - The company uses a one-year (12-month) period as its normal operating cycle for classifying assets and liabilities and uses the Renminbi (RMB) as its functional currency[151](index=151&type=chunk)[152](index=152&type=chunk) - The company has formulated specific accounting policies and estimates for transactions or events such as financial instrument impairment, fixed asset depreciation, intangible asset amortization, and revenue recognition[148](index=148&type=chunk) [Taxes](index=76&type=section&id=8.6%20Taxes) The company benefits from a 15% preferential income tax rate as a high-tech enterprise Main Taxes and Rates | Tax Type | Rate | | :--- | :--- | | Value-Added Tax (VAT) | 13%, 6%, 5% | | Urban Maintenance and Construction Tax | 7% | | Corporate Income Tax | 15%, 20% | | Education Surcharge | 3% | | Local Education Surcharge | 2% | - The company is recognized as a high-tech enterprise and is subject to a reduced corporate income tax rate of **15%**[249](index=249&type=chunk) - The subsidiary, Zhejiang Xinguang Pharmaceutical Technology Co, Ltd, qualifies as a small and micro-enterprise and enjoys a preferential corporate income tax rate of **20%** on 25% of its taxable income[249](index=249&type=chunk) - The company benefits from a **5%** additional VAT deduction for advanced manufacturing enterprises and a **50%** reduction in "six taxes and two fees" for small and micro-enterprises[250](index=250&type=chunk)[252](index=252&type=chunk) [Notes to Consolidated Financial Statement Items](index=77&type=section&id=8.7%20Notes%20to%20Consolidated%20Financial%20Statement%20Items) This section provides detailed notes on items in the consolidated financial statements, including assets, liabilities, and income Cash and Cash Equivalents | Item | Closing Balance (CNY) | Opening Balance (CNY) | | :--- | :--- | :--- | | Cash on Hand | 4,676.49 | 2,001.93 | | Bank Deposits | 304,788,175.14 | 502,031,958.76 | | Other Monetary Funds | 1,528,744.42 | 1,382,164.77 | | Total | 306,321,596.05 | 503,416,125.46 | Trading Financial Assets | Item | Closing Balance (CNY) | Opening Balance (CNY) | | :--- | :--- | :--- | | Structured Deposits | 370,000,000.00 | 185,000,000.00 | | Total | 370,000,000.00 | 185,000,000.00 | Accounts Receivable | Category | Closing Book Value (CNY) | Opening Book Value (CNY) | | :--- | :--- | :--- | | Accounts Receivable | 10,831,408.99 | 11,800,922.88 | | Bad Debt Provision | 2,003,617.98 | 2,058,180.98 | Operating Revenue and Costs | Item | Current Period Revenue (CNY) | Current Period Costs (CNY) | Prior Period Revenue (CNY) | Prior Period Costs (CNY) | | :--- | :--- | :--- | :--- | :--- | | Main Business | 140,882,733.58 | 89,277,685.97 | 146,152,540.08 | 96,414,345.44 | | Other Business | 60,195.62 | 86,125.68 | 57,497.94 | 85,590.42 | | Total | 140,942,929.20 | 89,363,811.65 | 146,210,038.02 | 96,499,935.86 | Financial Expenses | Item | Current Period Amount (CNY) | Prior Period Amount (CNY) | | :--- | :--- | :--- | | Interest | -10,666,340.74 | -3,863,048.33 | | Bank Service Fees | 7,347.00 | 7,658.06 | | Total | -10,658,993.74 | -3,855,390.27 | [R&D Expenses](index=128&type=section&id=8.8%20R&D%20Expenses) Total R&D expenditure for the period was CNY 6.99 million, all of which was expensed R&D Expense Breakdown | Item | Current Period Amount (CNY) | Prior Period Amount (CNY) | | :--- | :--- | :--- | | Direct Inputs | 1,723,836.35 | 3,775,058.25 | | Salaries and Wages | 2,710,532.69 | 1,958,503.61 | | Depreciation | 1,163,664.40 | 1,169,667.38 | | Outsourced Research Fees | 1,220,000.00 | 0.00 | | Other | 167,709.21 | 52,391.79 | | Total | 6,985,742.65 | 6,955,621.03 | | Of which: Expensed R&D | 6,985,742.65 | 6,955,621.03 | - All R&D expenditure in the current period was expensed, with no capitalized R&D expenditure[525](index=525&type=chunk) [Changes in Consolidation Scope](index=129&type=section&id=8.9%20Changes%20in%20Consolidation%20Scope) No changes in the scope of consolidation occurred during the reporting period - There were no business combinations involving enterprises not under common control during the period[530](index=530&type=chunk) - There were no business combinations involving enterprises under common control during the period[534](index=534&type=chunk) - There were no transactions or events resulting in the loss of control over a subsidiary during the period[536](index=536&type=chunk) [Interests in Other Entities](index=133&type=section&id=8.10%20Interests%20in%20Other%20Entities) The company holds a 100% interest in its wholly-owned subsidiary, Zhejiang Xinguang Pharmaceutical Technology Co, Ltd Composition of the Corporate Group | Subsidiary Name | Registered Capital (CNY) | Principal Place of Business | Place of Registration | Business Nature | Shareholding Ratio (Direct) | | :--- | :--- | :--- | :--- | :--- | :--- | | Zhejiang Xinguang Pharmaceutical Technology Co, Ltd | 35,000,000.00 | Hangzhou | Hangzhou | Pharmaceutical Manufacturing | 100.00% | - The company had no significant non-wholly-owned subsidiaries during the reporting period[539](index=539&type=chunk) - The company had no significant joint ventures or associates during the reporting period[543](index=543&type=chunk)[545](index=545&type=chunk) [Government Grants](index=138&type=section&id=8.11%20Government%20Grants) The company received CNY 0.89 million in government grants included in current profit and loss Liability Items Related to Government Grants | Account | Opening Balance (CNY) | Current Period Decrease (CNY) | Closing Balance (CNY) | Asset/Income Related | | :--- | :--- | :--- | :--- | :--- | | Deferred Income | 6,281,745.36 | 692,974.80 | 5,588,770.56 | Asset-related | Government Grants Included in Current Profit and Loss | Account | Current Period Amount (CNY) | Prior Period Amount (CNY) | | :--- | :--- | :--- | | Government grants included in other income | 885,843.80 | 996,618.40 | [Risks Related to Financial Instruments](index=138&type=section&id=8.12%20Risks%20Related%20to%20Financial%20Instruments) The company manages credit, liquidity, and market risks to balance risk and return - The company's risk management objective is to achieve a balance between risk and return, minimizing the negative impact of risks on its operating performance to maximize shareholder value[552](index=552&type=chunk) - The company faces **credit risk, liquidity risk, and market risk** in its daily activities[552](index=552&type=chunk) - Credit risk arises mainly from cash and receivables, which is managed by placing funds with highly-rated financial institutions and regularly assessing customer credit[558](index=558&type=chunk)[560](index=560&type=chunk)[561](index=561&type=chunk) - Liquidity risk is controlled by using a variety of financing instruments and optimizing the financing structure with a mix of long-term and short-term financing[563](index=563&type=chunk) - The company does not engage in hedging activities for risk management[565](index=565&type=chunk) [Fair Value Disclosure](index=141&type=section&id=8.13%20Fair%20Value%20Disclosure) Assets measured at fair value totaled CNY 391.95 million, primarily consisting of structured deposits and wealth management products Fair Value of Assets and Liabilities at Period-End | Item | Level 1 Fair Value (CNY) | Level 2 Fair Value (CNY) | Level 3 Fair Value (CNY) | Total (CNY) | | :--- | :--- | :--- | :--- | :--- | | Structured Deposits and Wealth Management Products | | 370,000,000.00 | | 370,000,000.00 | | Other Equity Instrument Investments | 4,777,474.20 | | 16,900,000.00 | 21,677,474.20 | | Notes Receivable Financing | | | 274,738.70 | 274,738.70 | | Total Assets at Fair Value | 4,777,474.20 | 370,000,000.00 | 17,174,738.70 | 391,952,212.90 | - The fair value of other equity instrument investments (stocks) is based on the closing price on the last trading day near the balance sheet date[569](index=569&type=chunk) - The fair value of trading financial assets (structured deposits) is based on available market information and value parameters[570](index=570&type=chunk) - Notes receivable financing and some other equity instrument investments are valued at cost as their fair value cannot be reliably measured[571](index=571&type=chunk) [Related Parties and Transactions](index=143&type=section&id=8.14%20Related%20Parties%20and%20Transactions) No major related-party transactions occurred during the period, except for one leasing arrangement where the company is the lessor - The company did not engage in related-party transactions for the purchase or sale of goods or the provision and receipt of services[576](index=576&type=chunk) - The company had no related-party entrustment management/contracting or entrusted management/outsourcing arrangements[577](index=577&type=chunk)[578](index=578&type=chunk) - The company has one related-party lease as a lessor, with the specific amount not disclosed[579](index=579&type=chunk)[580](index=580&type=chunk) - The company had no related-party guarantees, fund lending, asset transfers, or debt restructuring[582](index=582&type=chunk)[583](index=583&type=chunk)[584](index=584&type=chunk)[585](index=585&type=chunk) [Share-based Payment](index=146&type=section&id=8.15%20Share-based%20Payment) The company had no share-based payment arrangements during the reporting period - The company had no overall share-based payment situation during the reporting period[591](index=591&type=chunk) [Commitments and Contingencies](index=146&type=section&id=8.16%20Commitments%20and%20Contingencies) As of the balance sheet date, the company had no significant commitments or contingencies to disclose - As of the balance sheet date, the company had no significant commitments to disclose[592](index=592&type=chunk) - As of the balance sheet date, the company had no significant contingencies to disclose[593](index=593&type=chunk)[594](index=594&type=chunk) [Post-Balance Sheet Events](index=147&type=section&id=8.17%20Post-Balance%20Sheet%20Events) No significant post-balance sheet events occurred - The company had no significant non-adjusting events after the reporting period[596](index=596&type=chunk) - The company had no profit distribution plans after the reporting period[597](index=597&type=chunk) [Other Significant Matters](index=147&type=section&id=8.18%20Other%20Significant%20Matters) The company's primary business is managed as a single segment, thus no segment information is disclosed - The company had no other significant matters such as prior period accounting error corrections, debt restructuring, asset swaps, annuity plans, or discontinued operations[598](index=598&type=chunk)[600](index=600&type=chunk)[601](index=601&type=chunk)[602](index=602&type=chunk) - The company's main business is the production and sale of products like Huangqi Shengmai Yin, which is managed as a single integrated business, making segment information disclosure unnecessary[604](index=604&type=chunk) [Notes to Parent Company Financial Statement Items](index=149&type=section&id=8.19%20Notes%20to%20Parent%20Company%20Financial%20Statement%20Items) The parent company's investment income of CNY 2.11 million was mainly from financial assets and equity investments Parent Company Accounts Receivable | Category | Closing Book Value (CNY) | Opening Book Value (CNY) | | :--- | :--- | :--- | | Accounts Receivable | 12,014,508.99 | 11,800,922.88 | | Bad Debt Provision | 1,932,517.98 | 2,058,180.98 | Parent Company Other Receivables | Item | Closing Balance (CNY) | Opening Balance (CNY) | | :--- | :--- | :--- | | Other Receivables | 220,451.40 | 38,221.68 | | Bad Debt Provision | 39,021.51 | 31,648.05 | Parent Company Long-term Equity Investments | Item | Closing Book Value (CNY) | Opening Book Value (CNY) | | :--- | :--- | :--- | | Investment in Subsidiaries | 35,000,000.00 | 35,000,000.00 | | Total | 35,000,000.00 | 35,000,000.00 | Parent Company Operating Revenue and Costs | Item | Current Period Revenue (CNY) | Current Period Costs (CNY) | Prior Period Revenue (CNY) | Prior Period Costs (CNY) | | :--- | :--- | :--- | :--- | :--- | | Main Business | 139,394,591.98 | 89,277,685.97 | 145,095,504.70 | 96,414,345.44 | | Other Business | 60,195.62 | 86,125.68 | 57,497.94 | 85,590.42 | | Total | 139,454,787.60 | 89,363,811.65 | 145,153,002.64 | 96,499,935.86 | Parent Company Investment Income | Item | Current Period Amount (CNY) | Prior Period Amount (CNY) | | :--- | :--- | :--- | | Investment income from disposal of trading financial assets | 1,723,197.22 | 2,004,538.65 | | Dividend income from other equity instrument investments | 385,842.88 | 285,746.60 | | Total | 2,109,040.10 | 2,290,285.25 | [Supplementary Information](index=159&type=section&id=8.20%20Supplementary%20Information) Non-recurring profit and loss totaled CNY 2.47 million, and the weighted average return on equity was 3.80% Details of Current Non-recurring Profit and Loss | Item | Amount (CNY) | | :--- | :--- | | Gains/Losses on Disposal of Non-current Assets | -20,128.57 | | Government Subsidies Included in Current Profit/Loss | 885,843.80 | | Gains/Losses from Fair Value Changes and Disposal of Financial Assets and Liabilities | 1,799,444.32 | | Other Non-operating Income and Expenses | 229,899.70 | | Less: Income Tax Impact | 426,634.18 | | Total | 2,468,425.07 | Return on Equity and Earnings Per Share | Reporting Period Profit | Weighted Average Return on Equity | Basic EPS (CNY/Share) | Diluted EPS (CNY/Share) | | :--- | :--- | :--- | :--- | | Net profit attributable to ordinary shareholders | 3.80% | 0.20 | 0.20 | | Net profit attributable to ordinary shareholders after deducting non-recurring items | 3.51% | 0.18 | 0.18 |